Melanoma tumor-associated antigens (Melanoma TAAs)

Melanoma tumor-associated antigens (TAAs) derived from allogeneic melanoma cell membranes constitute a complex mixture of immunogenic molecules used in active immunotherapy. These antigens, which include proteins like MART-1, gp100, and tyrosinase, as well as gangliosides like GD2 and GD3, are presented to the patient's immune system to elicit a broad-spectrum anti-tumor response (Morton et al., 1992, Ann Surg). The use of allogeneic (donor-derived) cell lines ensures a wide variety of epitopes are available, addressing the high mutational burden and antigenic heterogeneity characteristic of melanoma (Hsueh et al., 1998, J Clin Oncol). When administered, these antigens are processed by professional antigen-presenting cells, leading to the activation of cytotoxic T lymphocytes and the production of antibodies. This therapeutic strategy is designed to provide long-term immunosurveillance and target micrometastatic disease. While historical allogeneic whole-cell vaccines like Canvaxin faced challenges in Phase III clinical trials, the underlying antigens remain critical targets for modern vaccine and TCR-T cell therapies (Sondak et al., 2006, J Clin Oncol).

Other names

Melanoma-associated antigensAllogeneic melanoma cell vaccine antigensPolyvalent melanoma antigensTumor-associated antigens (TAA)Melanoma cell membrane antigens

Induction of active specific immunotherapy by presenting a broad spectrum of allogeneic melanoma-derived epitopes to the host immune system, thereby stimulating polyvalent cytotoxic T-lymphocyte and humoral responses against endogenous tumor cells.